Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts

Blood

Volumn 118, Issue 20, 2011, Pages 5583-5592

  Blau, Olga ^a   Baldus, Claudia Dorothea ^a   Hofmann, Wolf Karsten ^b   Thiel, Gundula ^c   Nolte, Florian ^b   Burmeister, Thomas ^a   Türkmen, Seval ^a   Benlasfer, Ouidad ^a   Schümann, Elke ^c   Sindram, Annette ^a   Molkentin, Mara ^a   Mundlos, Stefan ^a   Keilholz, Ulrich ^a   Thiel, Eckhard ^a   Blau, Igor Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Out Patients' Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MESENCHYME CELL; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PRIORITY JOURNAL; STROMA CELL;

EID: 81555196340     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-343467     Document Type: Article

References (36)

1. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol. 2008;142(5):695-708.
2. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
3. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
4. Estey E. High cytogenetic or molecular genetic risk acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:474-480.
5. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395. (Pubitemid 351377805)
6. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18(1):120-125. (Pubitemid 38159447)
7. Mrózek K, Heerema NA, Blomfeld CD. Cytogeneics in acute leukemia. Blood Rev. 2004;18:115-36.
8. Bacher U, Schnittger S, Haferlach C, Haferlach T. Molecular diagnostics in acute leukemias. Clin Chem Lab Med. 2009;47(11):1333-1341.
9. Baldus C, Mrozek K, Marcucci G, Bloomfeld CD. Clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol. 2007;137:387-400. (Pubitemid 46698282)
10. Gaidzik V, Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol. 2008;35(4):346-355.
11. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59-66. (Pubitemid 35177429)
12. + AML): biologic and clinical features. Blood. 2007;109(3):874-885.
13. Knudson A. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820-823.
14. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007;20(4):597-612. (Pubitemid 350215375)
15. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009;12(4):103-113.
16. Borojevic R, Roela R, Rodarte R, et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk Res. 2004;28(8):831-844. (Pubitemid 38760045)
17. Flores-Figueroa E, Montesinos JJ, Flores-Guzman P, et al. Functional analysis of myelodysplastic syndrome-derived mesenchymal stem cells. Leuk Res. 2008;32(9):1407-1416.
18. Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713-1724.
19. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia. Nature. 2010;464:852-857.
20. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 2007;129(6):1081-1095. (Pubitemid 46908695)
21. Blau O, Hofmann WK, Baldus CD, et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol. 2007;35(2):221-229. (Pubitemid 46135819)
22. Flores-Figueroa E, Arana-Trejo RM, Gutiérrez-Espíndola G, Pérez-Cabrera A, Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res. 2005;29(2):215-224. (Pubitemid 39647516)
23. Lopez-Villar O, Garcia JL, Sancez-Guijo FM, et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia. 2009;23:664-672.
24. Klaus M, Stavroulaki E, Kastrinaki MC, et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2010;19(7):1043-1055.
25. Roela R, Carraro DM, Brentani HP, et al. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes. Leuk Res. 2007;31(5):579-589. (Pubitemid 46560005)
26. Soenen-Cornu V, Tourino C, Bonnet ML, et al.Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene. 2005;24:2441-2448. (Pubitemid 40593035)
27. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
28. Rieger K, Marinets O, Fietz T, et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol. 2005;33(5):605-611. (Pubitemid 40592178)
29. Shaffer LG, Slovak ML, Campbell LJ, eds. ISCN (2009): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2009.
30. Burmeister T, Marschalek R, Schneider B, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20(3):451-457. (Pubitemid 43291743)
31. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-3746. (Pubitemid 41739007)
32. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191-192.
33. Wong AK, Fang B, Zhang L, Guo X, Lee S, Schreck R. Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? Arch Pathol Lab Med. 2008;132(8):1329-1332.
34. Zhang Z-X, Guan LX, Zhang K, et al. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int. 2007;31(6):645-648. (Pubitemid 46660640)
35. Bernardo ME, Zaffaron N, Novara F, et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142-9149. (Pubitemid 47535900)
36. Ramakrishnan A, Deeg HJ. A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther. 2009;9(1):21-28.